MRK Merck & Co. (MRK) Q4 FY25 earnings call
Merck delivered solid Q4 FY25 results, driven by strong performances in oncology and Animal Health, alongside increasing contributions from new product launches. The company is actively transforming its portfolio, with line of sight to over $70 billion in commercial opportunity by the mid-2030s, bolstered by strategic acquisitions and a robust pipeline. Management expresses high confidence in sustainable long-term growth post-KEYTRUDA LOE, with significant clinical milestones anticipated in the coming years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
MRK operating KPIs by quarter
| KPI | Dec 2024 Q4 FY24 | Mar 2025 Q1 FY25 | Sep 2025 Q3 FY25 | This call Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|---|
| Patients WINREVAIR - US | ~1,500Approximately 1,500 new patients in the US received a prescription, bringing the total number of new patients prescribed to approximately 5,200 since launch.Source: earnings call transcript | 1,400+In the US, more than 1,400 new patients received a prescription during the quarter.Source: earnings call transcript | ~1,500In the US, approximately 1,500 new patients received a prescription and over 24,000 total prescriptions were dispensed in the quarter, a testament to the continued strong demand for this important treatment option.Source: earnings call transcript | 1,500+In the US, more than 1,500 new patients received a prescription and over 27,000 total prescriptions were dispensed.Source: earnings call transcript | 1,600+In the US, we continued to see steady progress with more than 1,600 new patients having received a prescription and an increase in usage by patients with background therapies do not include a prostacyclin.Source: earnings call transcript | — |
| Prescriptions filled WINREVAIR - US | — | — | 24K+In the US, approximately 1,500 new patients received a prescription and over 24,000 total prescriptions were dispensed in the quarter, a testament to the continued strong demand for this important treatment option.Source: earnings call transcript | 27K+In the US, more than 1,500 new patients received a prescription and over 27,000 total prescriptions were dispensed.Source: earnings call transcript | — | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.